Immune Design Corp. Company Profile (NASDAQ:IMDZ)

About Immune Design Corp. (NASDAQ:IMDZ)

Immune Design Corp. logoImmune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMDZ
  • CUSIP: N/A
  • Web:
  • Market Cap: $253.63 million
  • Outstanding Shares: 25,620,000
Average Prices:
  • 50 Day Moving Avg: $9.58
  • 200 Day Moving Avg: $8.01
  • 52 Week Range: $4.50 - $13.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.62
  • P/E Growth: -0.87
Sales & Book Value:
  • Annual Revenue: $16.46 million
  • Price / Sales: 16.11
  • Book Value: $2.87 per share
  • Price / Book: 3.61
  • EBIDTA: ($47,730,000.00)
  • Net Margins: -324.33%
  • Return on Equity: -59.14%
  • Return on Assets: -49.55%
  • Current Ratio: 5.21%
  • Quick Ratio: 5.17%
  • Average Volume: 195,128 shs.
  • Beta: 2.81
  • Short Ratio: 7.87

Frequently Asked Questions for Immune Design Corp. (NASDAQ:IMDZ)

What is Immune Design Corp.'s stock symbol?

Immune Design Corp. trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design Corp.'s earnings last quarter?

Immune Design Corp. (NASDAQ:IMDZ) issued its quarterly earnings results on Wednesday, August, 2nd. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.11. The business earned $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. View Immune Design Corp.'s Earnings History.

When will Immune Design Corp. make its next earnings announcement?

Immune Design Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Immune Design Corp..

Where is Immune Design Corp.'s stock going? Where will Immune Design Corp.'s stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for Immune Design Corp.'s stock. Their forecasts range from $18.00 to $20.00. On average, they anticipate Immune Design Corp.'s share price to reach $19.00 in the next year. View Analyst Ratings for Immune Design Corp..

What are analysts saying about Immune Design Corp. stock?

Here are some recent quotes from research analysts about Immune Design Corp. stock:

  • 1. According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 is being evaluated for soft tissue sarcoma and G100 for Merkel cell carcinoma , follicular non-Hodgkin Lymphoma and sarcoma. The company expects to provide data this year on both the lead product candidate from both monotherapy and combination studies to support their potential registration paths towards commercialization. We are positive on its strategic agreements with companies like Sanofi, Roche, and Merck, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. The company’s shares have outperformed the Medical-Drugs industry year to date. Loss estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in the recent quarters." (7/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Who are some of Immune Design Corp.'s key competitors?

Who are Immune Design Corp.'s key executives?

Immune Design Corp.'s management team includes the folowing people:

  • Edward E. Penhoet Ph., D., Independent Chairman of the Board
  • Carlos V. Paya M.D., Ph.D., President, Chief Executive Officer, Director
  • Stephen R. Brady J.D., Executive Vice President, Strategy & Finance
  • Sergey Yurasov M.D., Ph.D., Senior Vice President, Clinical Development, and Chief Medical Officer
  • Jan Henrik Ter Meule M.D., Chief Scientific Officer
  • Melanie Morrison, Vice President - Oncology Platform Leader
  • Heidi Petersen, Vice President - Regulatory Affairs
  • Wayne R. Gombotz Ph.D., Chief Development Officer
  • David Baltimore Ph.D., Independent Director
  • Franklin M. Berger, Independent Director

Who owns Immune Design Corp. stock?

Immune Design Corp.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Versant Venture Management LLC (8.64%), Victory Capital Management Inc. (7.72%), Franklin Resources Inc. (2.97%), JPMorgan Chase & Co. (2.07%), Vanguard Group Inc. (2.05%) and FMR LLC (1.61%). Company insiders that own Immune Design Corp. stock include Carlos V Paya, Franklin M Berger, Group L P Column, Lewis W Coleman, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design Corp..

Who sold Immune Design Corp. stock? Who is selling Immune Design Corp. stock?

Immune Design Corp.'s stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, FMR LLC and State Street Corp. Company insiders that have sold Immune Design Corp. stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design Corp..

Who bought Immune Design Corp. stock? Who is buying Immune Design Corp. stock?

Immune Design Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management LLC, JPMorgan Chase & Co., Sectoral Asset Management Inc, Numeric Investors LLC, Vanguard Group Inc., Nationwide Fund Advisors, Wells Fargo & Company MN and Northern Trust Corp. Company insiders that have bought Immune Design Corp. stock in the last two years include Group L P Column, Lewis W Coleman and Stephen R Brady. View Insider Buying and Selling for Immune Design Corp..

How do I buy Immune Design Corp. stock?

Shares of Immune Design Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Design Corp.'s stock price today?

One share of Immune Design Corp. stock can currently be purchased for approximately $10.35.

MarketBeat Community Rating for Immune Design Corp. (NASDAQ IMDZ)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Immune Design Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immune Design Corp. (NASDAQ:IMDZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (83.57% upside)

Analysts' Ratings History for Immune Design Corp. (NASDAQ:IMDZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$20.00LowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$18.00MediumView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyHighView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
5/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Immune Design Corp. (NASDAQ:IMDZ)
Earnings by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Earnings History by Quarter for Immune Design Corp. (NASDAQ IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.65)($0.54)$1.50 million$0.73 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immune Design Corp. (NASDAQ:IMDZ)
2017 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.61)($0.55)($0.58)
Q2 20172($0.65)($0.60)($0.63)
Q3 20172($0.74)($0.64)($0.69)
Q4 20172($0.76)($0.66)($0.71)
(Data provided by Zacks Investment Research)


Dividend History for Immune Design Corp. (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immune Design Corp. (NASDAQ:IMDZ)
Insider Ownership Percentage: 42.90%
Institutional Ownership Percentage: 51.46%
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Insider Trades by Quarter for Immune Design Corp. (NASDAQ:IMDZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2017Wayne GombotzInsiderSell10,000$11.43$114,300.00View SEC Filing  
7/11/2017Lewis W ColemanDirectorBuy12,000$9.05$108,600.00View SEC Filing  
7/10/2017Lewis W ColemanDirectorBuy10,000$9.00$90,000.00View SEC Filing  
7/7/2017Lewis W ColemanDirectorBuy8,000$9.27$74,160.00View SEC Filing  
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immune Design Corp. (NASDAQ:IMDZ)
Latest Headlines for Immune Design Corp. (NASDAQ:IMDZ)
DateHeadline logo Analysts Anticipate Immune Design Corp. (IMDZ) Will Announce Quarterly Sales of $620,000.00 - September 17 at 11:48 AM logoZacks: Analysts Expect Immune Design Corp. (IMDZ) to Announce -$0.68 Earnings Per Share - September 15 at 4:28 AM logoImmune Design Corp. (IMDZ) Given Average Rating of "Buy" by Brokerages - September 14 at 10:22 PM logoRoyal Bank Of Canada Begins Coverage on Immune Design Corp. (IMDZ) - September 14 at 9:50 PM logoCompany Spotlight: Immune Design - September 9 at 3:54 AM logoNew Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response - September 8 at 10:53 PM logoWhy Is Immune Design (IMDZ) Down 6.8% Since the Last Earnings Report? - September 8 at 10:53 PM logoImmune Design to Present at Upcoming Investor Conferences in September - September 1 at 8:14 PM logoInterim data positive for Immune Design's prime boost vaccine candidate CMB305 in mid-stage soft tissue sarcoma study; shares ahead 5% - September 1 at 5:54 AM logoImmune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress - August 31 at 6:11 AM logoHolding for Harvey - August 30 at 1:16 AM logo Immune Design Corp. (IMDZ) Given Consensus Rating of "Strong Buy" by Brokerages - August 28 at 8:10 PM logoAnalysts Issue Forecasts for Immune Design Corp.'s Q3 2017 Earnings (IMDZ) - August 28 at 1:20 AM logoZacks: Analysts Anticipate Immune Design Corp (IMDZ) Will Announce Quarterly Sales of $1.20 Million - August 11 at 5:38 PM logo-$0.65 EPS Expected for Immune Design Corp. (NASDAQ:IMDZ) This Quarter - August 9 at 7:52 AM logoJefferies Group Equities Analysts Reduce Earnings Estimates for Immune Design Corp. (IMDZ) - August 7 at 7:50 AM logoLeerink Swann Weighs in on Immune Design Corp.'s Q3 2017 Earnings (NASDAQ:IMDZ) - August 7 at 7:40 AM logoImmune Design Corp. (NASDAQ:IMDZ) Stock Rating Lowered by BidaskClub - August 5 at 2:24 PM logoJefferies Group Comments on Immune Design Corp.'s FY2021 Earnings (NASDAQ:IMDZ) - August 4 at 8:00 PM logoInsider Selling: Immune Design Corp. (NASDAQ:IMDZ) Insider Sells 10,000 Shares of Stock - August 3 at 9:04 PM logoImmune Design's (IMDZ) CEO Carlos Paya on Q2 2017 Results - Earnings Call Transcript - August 3 at 7:58 PM logoEdited Transcript of IMDZ earnings conference call or presentation 2-Aug-17 8:30pm GMT - August 3 at 7:58 PM logoImmune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2 - August 3 at 7:58 PM logoImmune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update - August 2 at 11:22 PM logoImmune Design reports 2Q loss - August 2 at 11:22 PM logoWhat's in the Cards for Immune Design (IMDZ) in Q2 Earnings? - July 31 at 7:14 PM logoWhat's in the Cards for Immune Design (IMDZ) in Q2 Earnings? - July 31 at 7:14 PM logoImmune Design Corp. (IMDZ) Scheduled to Post Earnings on Wednesday - July 27 at 12:15 PM logoImmune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update - July 26 at 8:06 PM logoAnalysts Anticipate Immune Design Corp. (NASDAQ:IMDZ) to Announce ($0.65) EPS - July 24 at 11:08 AM logoZacks: Brokerages Anticipate Immune Design Corp. (IMDZ) Will Post Earnings of -$0.65 Per Share - July 20 at 9:15 AM logoImmune Design Corp (NASDAQ:IMDZ) Upgraded at Zacks Investment Research - July 18 at 7:59 PM logoInsider Buying: Immune Design Corp. (NASDAQ:IMDZ) Director Purchases 12,000 Shares of Stock - July 12 at 8:18 PM logoLewis W. Coleman Buys 10,000 Shares of Immune Design Corp. (NASDAQ:IMDZ) Stock - July 12 at 8:16 PM logo3 Things In Biotech You Should Learn Today: July 11, 2017 - July 11 at 11:48 PM logoTuesday 7/11 Insider Buying Report: DLTR, IMDZ - July 11 at 11:48 PM logoImmune Design Corp. (NASDAQ:IMDZ) Director Lewis W. Coleman Purchases 8,000 Shares - July 10 at 10:58 PM logoForm 424B5 Immune Design Corp. - July 3 at 7:20 PM logoShort Interest in Immune Design Corp. (IMDZ) Grows By 42.7% - June 30 at 7:14 AM logoImmune Design Corp. (IMDZ) Rating Reiterated by Jefferies Group LLC - June 28 at 11:28 AM logoImmune Design (IMDZ) Shows Strength: Stock Moves 6.2% Higher - June 27 at 6:04 PM logoImmune Design Corp. (IMDZ) Expected to Announce Quarterly Sales of $1.50 Million - June 25 at 7:40 AM logoImmune Design Corp. (IMDZ) Lifted to "Sell" at ValuEngine - June 24 at 11:32 PM logoImmune Design Corp. (IMDZ) Expected to Announce Earnings of -$0.65 Per Share - June 23 at 10:20 PM logoZacks: Brokerages Set $22.00 Price Target for Immune Design Corp. (IMDZ) - June 21 at 7:48 AM logoImmune Design (IMDZ) Up 22.6% Since Earnings Report: Can It Continue? - June 9 at 9:37 AM logoImmune Design Corp (IMDZ) Earns "Buy" Rating from Cowen and Company - June 7 at 5:50 PM logoImmune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting - June 5 at 10:19 AM logo'ASCO' Boost For These 2 Small Oncology Plays? - June 4 at 6:04 PM logoImmune Design to Present at Jefferies 2017 Global Healthcare Conference - June 1 at 6:41 PM



Immune Design Corp. (IMDZ) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff